Clinical evaluation of the safety and efficacy of a timosaponin A‐III‐based antiwrinkle agent against skin aging

BACKGROUND: Timosaponin A‐III (TA‐III) is known to exist in the medicinal herb of Anemarrhena asphodeloides as one of major chemical components. AIMS: The photoprotective properties of TA‐III on UVB‐exposed HaCaT cells were evaluated on the antiwrinkle effects and skin safety in terms of clinical trial. METHODS: The level of matrix metalloproteinase (MMP)‐1, tissue inhibitor of metalloproteinases (TIMPs), and pro‐inflammatory cytokines were measured in HaCaT cells following UVB irradiation. To evaluate the clinical safety of an agent containing 0.25% of TA‐III for use on human skin. Female subjects (n = 21) between the ages of 43 and 55 who met the criteria for subject selection were selected. They were beginning to form or had already formed wrinkles. RESULTS: UVB irradiation increased MMP‐1 expression and pro‐inflammatory cytokines. These increases were attenuated by TA‐III pretreatment of UVB‐exposed HaCaT cells. We found that the agent containing 0.25% of TA‐III ameliorated skin wrinkling. A comparison between groups showed that wrinkle parameters were significantly reduced after 12 weeks of product use (P < 0.05). According to skin safety result, TA‐III showed no dermatological toxicity was found in participants. CONCLUSIONS: In conclusion, TA‐III could provide protection against photoaging and daily application of TA‐III for 12 weeks significantly reduced signs of facial aging by limiting wrinkle formation.